Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
Trial ID or NCT#
Status
Purpose
This randomized, pilot phase I trial studies whether phone or email reminders increases vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive material placed directly into or near a tumor to kill tumor cells. A reminder program may help increase use of vaginal dilators and decrease long-term side effects following brachytherapy.
Official Title
Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy
Eligibility Criteria
- * Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of their treatment* Patients cannot have previously received pelvic external beam radiation or brachytherapy. Patients may be enrolled while undergoing vaginal brachytherapy radiation treatment.* Patients should have a life expectancy of at least 1 year* No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status requirements* No organ and marrow function requirements* Ability to understand and the willingness to sign a written informed consent document
- * Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded* No restrictions regarding use of other investigational agents* No exclusion requirements due to co-morbid disease or intercurrent illness* No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device* No exclusion criteria relating to concomitant medications* No exclusion criteria for pregnant or nursing patients from participating in this study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a requirement for enrolling on this study)
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Dylann Fujimoto
650-723-8843
View on ClinicalTrials.gov